<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512980</url>
  </required_header>
  <id_info>
    <org_study_id>PVAG-14 pilot</org_study_id>
    <nct_id>NCT00512980</nct_id>
  </id_info>
  <brief_title>PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma</brief_title>
  <official_title>A Randomized Phase II Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Patients With Intermediate Stage Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in&#xD;
      patients with intermediate stage Hodgkin's lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lower recruitment rates as expected&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of Hodgkin's lymphoma&#xD;
&#xD;
          2. Stage&#xD;
&#xD;
               -  Clinical Stage IA, IB, IIA with at least one of the risk factors a-d given below&#xD;
&#xD;
               -  Clinical Stage IIB with one or both risk factors c-d given below risk factors:&#xD;
&#xD;
                    -  Large mediastinal mass (≥ 1/3 of the greatest thorax diameter as measured by&#xD;
                       chest x-ray)&#xD;
&#xD;
                    -  Extranodal involvement&#xD;
&#xD;
                    -  High erythrocyte sedimentation rate (≥ 50 mm/h in patients without&#xD;
                       B-symptoms, ≥ 30 mm/h in patients with B-symptoms)&#xD;
&#xD;
                    -  Three or more involved lymph node areas&#xD;
&#xD;
          3. No prior therapy for Hodgkin's lymphoma (exception: pre-phase treatment with&#xD;
             corticosteroids and vinca-alkaloids for a maximum of seven days may not preclude trial&#xD;
             participation if clinically indicated and all staging examinations have been&#xD;
             performed; all forms of prior radiotherapy preclude trial participation)&#xD;
&#xD;
          4. Age: 18-60 years&#xD;
&#xD;
          5. Signed informed consent with understanding of the study procedures and the&#xD;
             investigational nature of the study&#xD;
&#xD;
          6. Patient agrees that personal data and tissue samples are provided to the GHSG&#xD;
             (protection of privacy as defined by law will be ensured)&#xD;
&#xD;
          7. Life expectancy &gt; 3 months according to investigator judgement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Incomplete diagnosis of stage of disease&#xD;
&#xD;
          2. Prior or concurrent disease which prevents treatment according to protocol In&#xD;
             particular the following contraindications:&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease with global insufficiency&#xD;
&#xD;
               -  Symptomatic coronary heart disease&#xD;
&#xD;
               -  Cardiomyopathy or cardiac insufficiency (NYHA value of EF &lt; 50% or FS &lt; 25%)&#xD;
&#xD;
               -  Serious uncontrolled hypertension&#xD;
&#xD;
               -  Uncontrollable infection&#xD;
&#xD;
               -  Leucocyte concentration &lt; 3.000/mm3 or thrombocyte concentration &lt; 100.000/mm3&#xD;
&#xD;
               -  Creatinin clearance &lt; 60 ml/min&#xD;
&#xD;
               -  Bilirubin &gt; 2 mg/dl or GPT &gt; 100 U/l or GOT &gt; 100 U/I (exception: elevated values&#xD;
                  of Hodgkin's disease liver involvement)&#xD;
&#xD;
               -  HIV-Infection according to HIV test&#xD;
&#xD;
               -  Chronic or acute Hepatitis&#xD;
&#xD;
          3. HD as composite lymphoma&#xD;
&#xD;
          4. Prior chemotherapy or radiation&#xD;
&#xD;
          5. Malignant disease within the last 5 years (exceptions: basalioma, carcinoma in situ of&#xD;
             the cervix uteri, completely resected melanoma TNMpT1)&#xD;
&#xD;
          6. Pregnancy, lactation, positive pregnancy test&#xD;
&#xD;
          7. Refusal to use effective contraception&#xD;
&#xD;
          8. WHO performance index &gt; 2&#xD;
&#xD;
          9. Long-term ingestion of corticosteroids (e.g. for chronic polyarthritis) or&#xD;
             antineoplastic drugs (e.g. methotrexate)&#xD;
&#xD;
         10. Patient's lack of accountability, inability to appreciate the nature, meaning and&#xD;
             consequences of the trial and to formulate his/her own wishes correspondingly&#xD;
&#xD;
         11. Non compliance: Refusal of blood products during treatment, epilepsy, drug dependency,&#xD;
             change of residence abroad, prior cerebral injury or similar circumstances which&#xD;
             appear to make protocol treatment or long-term follow-up impossible&#xD;
&#xD;
         12. Antiepileptic treatment&#xD;
&#xD;
         13. General intolerance of any protocol medication&#xD;
&#xD;
         14. Any contraindication for study medication according to the summaries of product&#xD;
             information&#xD;
&#xD;
         15. Simultaneous participation in another clinical&#xD;
&#xD;
         16. Institutionalization by law&#xD;
&#xD;
         17. Relation of dependence with the sponsor's representative / trialist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Engert, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Andreas Engert</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>intermediate stages</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

